工程化大肠杆菌Nissle菌株可预防1型酪氨酸血症小鼠模型的致死性肝损伤
研究构建了在肠道厌氧条件下表达酪氨酸代谢基因的工程化大肠杆菌Nissle 1917(EcN-HT),在体外可消耗酪氨酸并产生左旋多巴。在Fah敲除小鼠(1型酪氨酸血症模型)中,口服EcN-HT增强酪氨酸降解、减少毒性代谢物蓄积并防止致死性肝损伤,RNA测序显示其恢复了肝脏全局基因表达模式,且在小鼠肠道中安全且耐受良好。
要点
- EcN-HT在体外消耗酪氨酸并产生左旋多巴。
- Fah敲除小鼠口服EcN-HT后酪氨酸降解增强、毒性代谢物蓄积减少,免于致死性肝损伤。
- EcN-HT治疗在小鼠肠道中被发现安全且耐受良好。
核心结论
- 这是首次报道可降解酪氨酸并减轻1型酪氨酸血症小鼠致死性肝损伤的工程化活菌。
- EcN-HT是一种有潜力治疗该病的新型工程化益生菌。
研究设计与样本
- 研究构建了在肠道厌氧条件下表达酪氨酸代谢相关基因的工程化大肠杆菌Nissle 1917(EcN-HT)。
- 在Fah敲除小鼠(公认的1型酪氨酸血症模型)中评估其降解酪氨酸和保护致死性肝损伤的能力,指标包括体重、生存率、血浆酪氨酸/肝功能、H&E染色和RNA测序。
主要发现
- EcN-HT在体外系统中消耗酪氨酸并产生左旋多巴。
- 在Fah敲除小鼠中,口服EcN-HT增强酪氨酸降解、减少毒性代谢物蓄积并防止致死性肝损伤。
- RNA测序分析显示EcN-HT恢复了Fah敲除小鼠肝脏的全局基因表达模式,尤其是涉及代谢信号和肝脏稳态的基因。
- EcN-HT治疗在小鼠肠道中被发现安全且耐受良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hereditary tyrosinemia type 1 (HT1) results from the loss of fumarylacetoacetate hydrolase (FAH) activity and can lead to lethal liver injury. Therapeutic options for HT1 remain limited. In this study, we aimed to construct an engineered bacterium capable of reprogramming host metabolism and thereby provide a potential alternative approach for the treatment of HT1. METHODS: Escherichia coli Nissle 1917 (EcN) was engineered to express genes involved in tyrosine metabolism in the anoxic conditions that are characteristic of the intestine (EcN-HT). Bodyweight, survival rate, plasma (tyrosine/liver function), H&E staining and RNA sequencing were used to assess its ability to degrade tyrosine and protect against lethal liver injury in Fah-knockout (KO) mice, a well-accepted model of HT1. RESULTS: EcN-HT consumed tyrosine and produced L-DOPA (levodopa) in an in vitro system. Importantly, in Fah-KO mice, the oral administration of EcN-HT enhanced tyrosine degradation, reduced the accumulation of toxic metabolites, and protected against lethal liver injury. RNA sequencing analysis revealed that EcN-HT rescued the global gene expression pattern in the livers of Fah-KO mice, particularly of genes involved in metabolic signaling and liver homeostasis. Moreover, EcN-HT treatment was found to be safe and well-tolerated in the mouse intestine. CONCLUSIONS: This is the first report of an engineered live bacterium that can degrade tyrosine and alleviate lethal liver injury in mice with HT1. EcN-HT represents a novel engineered probiotic with the potential to treat this condition. IMPACT AND IMPLICATIONS: Patients with hereditary tyrosinemia type 1 (HT1) are characterized by an inability to metabolize tyrosine normally and suffer from liver failure, renal dysfunction, neurological impairments, and cancer. Given the overlap and complementarity between the host and microbial metabolic pathways, the gut microbiome provides a potential chance to regulate host metabolism through degradation of tyrosine and reduction of byproducts that might be toxic. Herein, we demonstrated that an engineered live bacterium, EcN-HT, could enhance tyrosine breakdown, reduce the accumulation of toxic tyrosine byproducts, and protect against lethal liver injury in Fah-knockout mice. These findings suggested that engineered live biotherapeutics that can degrade tyrosine in the gut may represent a viable and safe strategy for the prevention of lethal liver injury in HT1 as well as the mitigation of its associated pathologies.
引用
- Gu P, Xie L, Chen T, et al. An engineered Escherichia coli Nissle strain prevents lethal liver injury in a mouse model of tyrosinemia type 1. J Hepatol. 2023. PMID: 37952766. doi:10.1016/j.jhep.2023.10.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。